The sustained efficacy and safety data through 3.5 years de-risks YORVIPATH's long-term profile and supports continued prescription growth. Monitor upcoming quarterly earnings for revenue ramp and any competitive developments.
ASND drugs
ASND drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 15 $223.29entry
- T+1 · 5mo ago +3.54%α +4.14% · $231.20
- T+5 · 5mo ago +2.11%α +3.49% · $228.00
- T+20 · 4mo ago +18.78%α +19.53% · $265.22
- T+60 · 2mo ago +16.80%α +15.80% · $260.81
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Ascendis Pharma announced sustained efficacy and safety data from the Phase 3 PaTHway Trial of TransCon PTH (YORVIPATH) in hypoparathyroidism through 3.5 years (Week 182). 86% of patients met the multi-component endpoint, 89% completed the trial, and key renal, bone, and quality-of-life benefits were maintained with no new safety signals. This positive long-term data reinforces the drug's profile and supports continued commercial adoption, though the stock has historically underperformed following prior positive reports.
Key Facts
- 86% of patients were responders for the multi-component endpoint (normocalcemia, no active vitamin D, ≤600 mg/day calcium) at Week 182.
- 89% of patients completed the 3.5-year trial.
- 100% of patients achieved independence from active vitamin D; 96% from therapeutic calcium doses.
- Mean eGFR increased by 11.0 mL/min/1.73 m² from baseline and was maintained through Week 182, contrasting with expected age-related decline.
- Mean 24-hour urine calcium normalized within 26 weeks and remained normal through Week 182.
- No new safety signals; no discontinuations related to study drug; no anti-PTH antibodies developed.
- TransCon PTH is already approved as YORVIPATH in the US, EU, and other jurisdictions.
- Trial enrolled 82 adults (85% post-surgical, 15% non-surgical hypoparathyroidism).
Financial Impact
Positive long-term data supports YORVIPATH's commercial potential in hypoparathyroidism, a chronic disease with no other PTH-replacement therapy. No revenue or financial figures were disclosed in the press release.
Risk Factors
- Competition from other hypoparathyroidism therapies in development.
- Pricing and reimbursement challenges in key markets.
- Potential for regulatory setbacks in additional jurisdictions.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3311416 |
Track record
41 reports on ASND
13 of 18 bullish or bearish reports moved the stock their way by T+60. Best: +26.62% at T+20 after the Jun 2, 2026 report. 24 of 26 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $271.96 Now $275.39 +1.26% settles Feb 12
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $275.39 Now $275.39 +0.00% settles Feb 11
- Nov 12, 20264d ago 6-K Bullish 6/10 Entry $267.07 Now $275.39 +3.12% settles Feb 10
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $267.07 Now $275.39 +3.12% settles Feb 10
- Nov 6, 202610d ago 6-K Bullish 6/10 Entry $259.85 Now $275.39 +5.98% settles Feb 5
- Nov 6, 202610d ago Press Release Bullish 6/10 Entry $256.82 Now $275.39 +7.23% settles Feb 4
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $253.45 Now $275.39 +8.66% settles Feb 3
- Nov 2, 202614d ago Institutional Cluster Bullish 4/10 Entry $250.17 Now $275.39 +10.08% settles Feb 1
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $245.85 Now $275.39 +12.02% settles Jan 25
- Oct 16, 20264w ago 6-K Bullish 7/10 Entry $225.25 Now $275.39 +22.26% settles Jan 13
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers